Jump Financial’s Dianthus Therapeutics DNTH Stock Holding History

Jump Financial’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.44M	Buy	+25,001	New	+$2.18M	0.02%	815
2024 Q2	–	Sell	-13,942	Closed	-$418K	–	1906
2024 Q1	$418K	Buy	+13,942	New	+$303K	0.01%	1280
2022 Q1	–	Sell	-641	Closed	-$45K	–	1629
2021 Q4	$45K	Buy	+641	New	+$64.4K	﹤0.01%	1316
2021 Q3	–	Sell	-1,469	Closed	-$230K	–	1185
2021 Q2	$230K	Buy	+1,469	New	+$270K	0.02%	789

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Jump Financial's DNTH Position: Q2 2026 in Review

Jump Financial opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 25,001 shares worth $2.44M. The stake represents 0.02% of the portfolio and ranks #815 among its holdings. This is a return to the name: Jump Financial previously reported a position in DNTH as recently as Q1 2024.

Jump Financial first reported a position in DNTH in Q2 2021 and has held it in 4 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Jump Financial held 25,001 shares of Dianthus Therapeutics worth $2.44M as of Q2 2026.
Dianthus Therapeutics was a new Jump Financial position in Q2 2026.
Dianthus Therapeutics made up 0.02% of Jump Financial's portfolio in Q2 2026, its #815 holding.
Jump Financial first reported a position in Dianthus Therapeutics in Q2 2021 and has held it in 4 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.